Free Trial
NYSE:PEN

Penumbra (PEN) Stock Price, News & Analysis

$178.41
-11.69 (-6.15%)
(As of 07/26/2024 ET)
Today's Range
$176.66
$191.53
50-Day Range
$172.40
$203.25
52-Week Range
$170.59
$310.51
Volume
552,683 shs
Average Volume
347,085 shs
Market Capitalization
$6.92 billion
P/E Ratio
75.28
Dividend Yield
N/A
Price Target
$260.56

Penumbra MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
46.0% Upside
$260.56 Price Target
Short Interest
Bearish
6.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.22
Upright™ Environmental Score
News Sentiment
0.39mentions of Penumbra in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$6.43 M Sold Last Quarter
Proj. Earnings Growth
35.76%
From $2.88 to $3.91 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.84 out of 5 stars

Medical Sector

30th out of 936 stocks

Surgical & Medical Instruments Industry

7th out of 101 stocks

PEN stock logo

About Penumbra Stock (NYSE:PEN)

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

PEN Stock Price History

PEN Stock News Headlines

I’m giving you the name of this investment for free
This key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documentary I will provide you with all the details of this one-of-a-kind investment.
Massif Capital Q2 2024 Letter To Investors
Penumbra (NYSE:PEN) PT Lowered to $230.00 at Truist Financial
I’m giving you the name of this investment for free
This key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documentary I will provide you with all the details of this one-of-a-kind investment.
Penumbra, Inc. (PEN)
See More Headlines
Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/07/2024
Today
7/27/2024
Next Earnings (Confirmed)
7/30/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Employees
4,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$260.56
High Stock Price Target
$337.00
Low Stock Price Target
$210.00
Potential Upside/Downside
+46.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$90.95 million
Pretax Margin
7.81%

Debt

Sales & Book Value

Annual Sales
$1.06 billion
Cash Flow
$2.61 per share
Book Value
$30.55 per share

Miscellaneous

Free Float
36,827,000
Market Cap
$6.92 billion
Optionable
Optionable
Beta
0.55
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

PEN Stock Analysis - Frequently Asked Questions

How have PEN shares performed this year?

Penumbra's stock was trading at $251.54 at the beginning of 2024. Since then, PEN stock has decreased by 29.1% and is now trading at $178.41.
View the best growth stocks for 2024 here
.

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) issued its earnings results on Tuesday, May, 7th. The company reported $0.41 earnings per share for the quarter, missing analysts' consensus estimates of $0.42 by $0.01. Penumbra's revenue was up 15.5% on a year-over-year basis.

What is Adam Elsesser's approval rating as Penumbra's CEO?

57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees.

Who are Penumbra's major shareholders?

Penumbra's top institutional shareholders include Baillie Gifford & Co. (1.59%), Bank of New York Mellon Corp (0.84%), Allspring Global Investments Holdings LLC (0.54%) and Retirement Systems of Alabama (0.12%). Insiders that own company stock include Adam Elsesser, Arani Bose, Johanna Roberts, Harpreet Grewal, Bridget O'rourke, Surbhi Sarna, Don W Kassing, Thomas Wilder and James Robert Pray.
View institutional ownership trends
.

How do I buy shares of Penumbra?

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ) and Netflix (NFLX).

This page (NYSE:PEN) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners